Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

Conclusions Erdafitinib was well tolerated in Japanese patients with advanced or refractory solid tumors.Trial Registration: NCT01962532.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research